Vimentin Antibody (2D1)

Vimentin is a type III intermediate filament (IF) protein, encoded by the VIM gene, that plays an essential role in cytoskeletal function and is largely expressed by mesenchymal cell such as endothelial cells, fibroblasts, and immune cells (1). Human vimentin monomer protein is 466 amino acids (aa) in length with a theoretical molecular weight of ~54 kDa (2). Vimentin protein contains a central rod domain composed of four alpha-helices which is flanked by an N-terminal head domain and C-terminal tail domain (1,3). Vimentin monomers dimerize to form more complex structures resulting in the assembly of eight tetramers, referred to as unit-length filaments, which then assemble into full-length intermediate filaments that are 10-12 nm wide (1,3,4).

Activated macrophages have been shown to secrete phosphorylated vimentin which can be stimulated by a variety of pathophysiological factors including oxidized low-density lipoproteins and TNF-alpha or inhibited by IL-10 (1). The vimentin protein is often expressed at the cell surface playing a role in cell-cell interactions, tissue damage and repair, immune response, and pathogen recognition (1). Vimentin functions in many cytoskeletal processes including cell migration, which is highlighted by its upregulation during epithelial-to-mesenchymal transition (EMT) (4,5). Vimentin is a commonly used marker for EMT and is expressed by many tumor types (5). For example, high metastasis of oral squamous cell carcinomas also showed high vimentin positive expression in immunohistochemical staining analysis (5). A number of vimentin targeting compounds are in cancer-related clinical trials, however, given the multifunctional role of vimentin, the effect of inhibition on non-malignant cells needs to be thoroughly examined (5).

References

1. Ramos, I., Stamatakis, K., Oeste, C. L., & Perez-Sala, D. (2020). Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21134675

2. Uniprot (P08670)

3. Morrow, C. S., & Moore, D. L. (2020). Vimentin's side gig: Regulating cellular proteostasis in mammalian systems. Cytoskeleton (Hoboken, N.J.). https://doi.org/10.1002/cm.21645

4. van Bodegraven, E. J., & Etienne-Manneville, S. (2020). Intermediate filaments against actomyosin: the david and goliath of cell migration. Current Opinion in Cell Biology. https://doi.org/10.1016/j.ceb.2020.05.006

5. Strouhalova, K., Prechova, M., Gandalovicova, A., Brabek, J., Gregor, M., & Rosel, D. (2020). Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. Cancers. https://doi.org/10.3390/cancers12010184

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 3 confirmed species: Human, Rat,  Human.

We have publications tested in 4 applications: ICC/IF, IF/IHC, IHC-P, WB.

Showing Publications 1 - 10 of 11. Show All 11 Publications. Collapse Publications.

Publications using NBP1-92687	Applications	Species
Duan X, Weng H, Shen G et al. Preliminary study on the expression of UHRF1 in early oral squamous cell carcinoma and its clinical prognostic value Research Square 2023-02-03 (IHC-P, Human)	IHC-P	Human
Chou CW, Hung CN, Chiu CH et al. Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination Nature communications 2023-10-17 [PMID: 37848444]
Manhas A, Tripathi D, Jagavelu K Involvement of HIF1?/Reg protein in the regulation of HMGB3 in myocardial infarction Vascular pharmacology 2023-07-17 [PMID: 37467910] (ICC/IF, Rat)	ICC/IF	Rat
Monleón-Guinot I, Milian L, Martínez-Vallejo P et al. Morphological Characterization of Human Lung Cancer Organoids Cultured in Type I Collagen Hydrogels: A Histological Approach International journal of molecular sciences 2023-06-14 [PMID: 37373279] (ICC/IF, Human) Details: 1:500 dilution	ICC/IF	Human
Wang W, Lin Y, Zhang F et al. Single cell transcriptomic analysis of human amnion identifies cell-specific signatures associated with membrane rupture and parturition Cell Biosci. 2022-05-18 [PMID: 35585644] (ICC/IF, Human)	ICC/IF	Human
Hamdan F, YlOsmAki E, Chiaro J et al. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids J Immunother Cancer 2021-11-01 [PMID: 34362830] (ICC/IF, Human)	ICC/IF	Human
Chandramohan Y, Jeganathan K, Sivanesan S et al. Assessment of human ovarian follicular fluid derived mesenchymal stem cells in chitosan/PCL/Zn scaffold for bone tissue regeneration Life Sci 2020-10-06 [PMID: 33031825] (WB, Human)	WB	Human
Park S, Song CS, Lin CL et al. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer Endocrinology 2020-01-02 [PMID: 31894239]
Chen, YC;Ou, MC;Fang, CW;Lee, TH;Tzeng, SL; High Glucose Concentrations Negatively Regulate the IGF1R/Src/ERK Axis through the MicroRNA-9 in Colorectal Cancer Cells 2019-04-08 [PMID: 30965609] (WB, Human)	WB	Human
Scimeca M, Urbano N, Bonfiglio R et al. Breast osteoblast-like cells: a new biomarker for the management of breast cancer. Br. J. Cancer. 2018-10-17 [PMID: 30327566] (IHC-P, Human)	IHC-P	Human
Qi M, Zhou Y, Liu J et al. AngII induces HepG2 cells to activate epithelial-mesenchymal transition. Exp Ther Med 2018-10-01 [PMID: 30233697] (IF/IHC, Human)	IF/IHC	Human
Show All 11 Publications. Collapse Publications.

Images	Ratings	Applications	Species	Date	Details
Enlarge	5 reviewed by: Verified Customer	Immunohistochemistry-microslice	Mouse	07/27/2017	View Summary Application Other Sample Tested Mouse cortex Species Mouse Lot 041813

Array NBP1-92687

• Vimentin Antibodies
• Vimentin ELISA Kits
• Vimentin Lysate
• Vimentin Proteins
• Vimentin Proteins and Enzyme